RPRX241115C37500
- 0.00
- 0.000.00%
Royalty Pharma Newsroom
Royalty Pharma Is Maintained at Buy by Citigroup
Royalty Pharma Analyst Ratings
Express News | Royalty Pharma : Citigroup Cuts Target Price to $40 From $60
Why Southern, Xcel Energy And Royalty Pharma Are Winners For Passive Income
Express News | Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be $0.21
Royalty Pharma To Go Ex-Dividend On November 15th, 2024 With 0.21 USD Dividend Per Share
October 11th (Eastern Time) - $Royalty Pharma(RPRX.US)$ is trading ex-dividend on November 15th, 2024.Shareholders of record on November 15th, 2024 will receive 0.21 USD dividend per share on
Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $51
Press Release: Royalty Pharma Declares Fourth Quarter 2024 Dividend
Royalty Pharma PLC (RPRX) Q2 2024 Earnings Call Highlights: Surpassing Growth Expectations and ...
Peering Into Royalty Pharma's Recent Short Interest
What Makes Royalty Pharma (RPRX) a New Buy Stock
TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $42
Royalty Pharma Strikes Deal on FDA-Approved Schizophrenia Drug
10 Health Care Stocks With Whale Alerts In Today's Session
S&P 500 Futures Up In Premarket Trading; Manhattan Associates, Casella Waste Sys Lag
Royalty Pharma Plc's (NASDAQ:RPRX) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Goldman Sachs Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $51
Goldman Sachs analyst Chris Shibutani maintains $Royalty Pharma(RPRX.US)$ with a buy rating, and maintains the target price at $51.According to TipRanks data, the analyst has a success rate of 46.3%
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
Ascendis Pharma Reaches $150 Mln Royalty Funding Agreement With Royalty Pharma; Stock Drops